OrbiMed’s Praxis Precision Medicines PRAX Stock Holding History

OrbiMed’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77M	Buy	230,100 +57,600	+33%	+$18.2M	1.43%	15
2026 Q1	$55.6M	Buy	172,500 +78,000	+83%	+$24.1M	1.1%	27
2025 Q4	$27.9M	Buy	+94,500	New	+$17.6M	0.57%	50
2024 Q2	–	Sell	-460,512	Closed	-$28.1M	–	122
2024 Q1	$28.1M	Buy	+460,512	New	+$20.7M	0.51%	52
2021 Q1	–	Sell	-17,040	Closed	-$14.1M	–	175
2020 Q4	$14.1M	Buy	+17,040	New	+$9.95M	0.12%	116

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed's PRAX Position: Q2 2026 in Review

OrbiMed increased its Praxis Precision Medicines (PRAX) stake by 33% in Q2 2026, buying an estimated $18.2M and bringing the position to 230,100 shares worth $77M. The position accounts for 1.43% of the portfolio, ranked #15.

OrbiMed first reported a position in PRAX in Q4 2020 and has held it in 5 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

OrbiMed held 230,100 shares of Praxis Precision Medicines worth $77M as of Q2 2026.
OrbiMed bought 57,600 Praxis Precision Medicines shares in Q2 2026, an estimated $18.2M.
Praxis Precision Medicines made up 1.43% of OrbiMed's portfolio in Q2 2026, its #15 holding.
OrbiMed first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 5 quarters since.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.